Clinical trials: Psilocybin
Major Depressive Disorder, Anhedonia
Psilocybin for Treatment-Resistant Depression
The purpose of this study is to evaluate the efficacy of psilocybin on the symptom of anhedonia in individuals with treatment-resistant major depressive disorder.
- Conditions
- Major Depressive Disorder, Anhedonia, Treatment Resistant Depression
- Trial name
- NCT06230757
- Testing
- Psilocybin 25mg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Colorado, Denver
PTSD
Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder
This study is a community-informed, pragmatic, open-label, phase 1 clinical trial of group-format psilocybin-assisted therapy (GPAT) for individuals with post-traumatic stress disorder (PTSD).
- Trial name
- GPAT (NCT07506395)
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of New Mexico
Depression
Psilocybin-Assisted Therapy as a Treatment for Depression
Depression is the leading cause of disability worldwide, affecting an estimated 300 million people. Despite available treatments, response rates remain modest, and treatment resistance is common.
- Trial name
- NCT07582120
- Testing
- Psilocybin (Usona Institute)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder
Psilocybin-assisted CBT for Depression
The primary objectives of this clinical investigation are to (1) determine the acceptability and feasibility of joining psilocybin-assisted therapy with cognitive-behavioral therapy (PA-CBT) for patients with depression, (2)…
- Trial name
- NCT05227612
- Testing
- Psilocybin, Cognitive behavioral therapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, Los Angeles
Cocaine-Related Disorders
Psilocybin-facilitated Treatment for Cocaine Use
The primary purpose of this study is to evaluate the feasibility and estimate the efficacy of psilocybin-facilitated treatment for cocaine use.
- Trial name
- NCT02037126
- Testing
- Psilocybin, Diphenhydramine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Alabama at Birmingham
Lung Non-Small Cell Carcinoma, Unipolar Depression
Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer
This phase II trial tests the safety and side effects of psilocybin in combination with therapy for the treatment of major depressive disorder in patients with non-small cell lung cancer.
- Trial name
- NCT07216404
- Testing
- Biospecimen Collection, Counseling, Interview
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Alan Davis
Methamphetamine Use Disorder, Substance-Related Disorders
Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder
The purpose of this research study is to investigate the safety and feasibility of two (2) oral doses of psilocybin when combined with behavioral support for methamphetamine use disorder (MUD).
- Conditions
- Methamphetamine Use Disorder, Substance-Related Disorders, Chemically-Induced Disorders, Substance Use Disorders
- Trial name
- NCT05322954
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Wisconsin, Madison
Obsessive - Compulsive Disorder
Psilocybin for Treatment of OCD-2
Previous research indicates that psilocybin, a drug that changes activity in brain areas believed to be involved in obsessive-compulsive disorder (OCD), might improve treatment for, and improve lives of, people diagnosed with…
- Trial name
- NCT06992999
- Testing
- Low Dose Psilocybin, High Dose Psilocybin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Francisco A Moreno
COPD (Chronic Obstructive Pulmonary Disease), ALS (Amyotrophic Lateral Sclerosis)
Psilocybin Therapy for Psychological Distress in Palliative Patients
The goal of this clinical trial is to evaluate whether psilocybin therapy can effectively treat depression and psychological distress in adult patients with COPD, ALS, MS, or APD who have at least 6 months life expectancy.
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease), ALS (Amyotrophic Lateral Sclerosis), MS (Multiple Sclerosis), Major Depressive Disorder (MDD)
- Trial name
- PsyPal (NCT06782724)
- Testing
- Psilocybin therapy
- Where
- 4 sites in Czechia, Denmark and 2 more
- Volunteers
- 108 people
- Sponsor
- University Medical Center Groningen
Treatment-resistant Depression
Does Psilocybin Require Psychedelic Effects to Treat Depression?
Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects.
- Trial name
- PSI-RIS (NCT05710237)
- Testing
- Psilocybin 25 mg, Risperidone 1 MG
- Where
- Canada
- Volunteers
- 41 people
- Sponsor
- Centre for Addiction and Mental Health
Cancer, Major Depressive Disorder
Two Doses of Psilocybin for the Treatment of MDD in Adults With Cancer
This is a Phase 2, single-center study to explore the efficacy, safety, and tolerability of up to two 25-mg doses of psilocybin administered at an interval of 9 to 10 weeks in patients with MDD and cancer.
- Trial name
- 2Dose (NCT05947383)
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Sunstone Medical
Refractory Depression, Treatment Resistant Depression
Psilocybin-Assisted Therapy in Treatment-Resistant Depression
The goal of this clinical trial is to test how well psilocybin-assisted therapy works in treating people with depression. The main questions this study aims to answer are: Does psilocybin with assisted therapy help improve…
- Trial name
- NCT06303739
- Testing
- psilocybin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of North Carolina, Chapel Hill
Major Depression
Study of Psilocybin Under Anesthesia Controlled by EEG
Major depressive disorder (MDD) affects millions of Americans and remains difficult to treat. Psilocybin, a psychedelic compound, has shown promise for reducing depression symptoms, but a key challenge in psychedelic research is…
- Trial name
- SPACE (NCT07479550)
- Testing
- Psilocybin (Usona Institute), Propofol
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanford University
Depression, Anxiety
Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of Depression
In this single-arm Phase 2 study, the researchers are assessing the feasibility of the group retreat format for clinicians and explores different 'doses' of preparation. A sequential dose-escalation design is used.
- Trial name
- NCT07565909
- Testing
- Psilocybin
- Volunteers
- 72 people
- Sponsor
- University of Washington
Depression - Major Depressive Disorder, Psilocybin
Group PACBT for Depression
This study will seek to determine the (1) acceptability and (2) feasibility of psilocybin as an adjunct to cognitive-behavioral therapy, delivered as a group treatment (G-PACBT) for major depressive disorder and (3) explore the…
- Conditions
- Depression - Major Depressive Disorder, Psilocybin, Cognitive Behavioral Therapy
- Trial name
- NCT07566104
- Testing
- Psilocybin (drug), Group Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, Los Angeles
Chronic Low-back Pain
Psilocybin Therapy for Chronic Low Back Pain
This study evaluates whether psilocybin therapy helps patients cope with chronic low back pain more effectively. Patients may be recruited at Stanford and University of California San Francisco (UCSF), study procedures will occur…
- Trial name
- POP (NCT05351541)
- Testing
- Psilocybin therapy with Zolpidem and Modafinil, Psilocybin therapy with Zolpidem, Psilocybin therapy with Modafinil
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Joshua Woolley, MD, PhD
Depressive Disorder, Major
A Study of Psilocybin for Major Depressive Disorder (MDD)
One hundred participants, ages 21 to 65, who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for major depressive disorder (MDD) will be stratified by study site and randomized with a 1-to-1 allocation…
- Trial name
- NCT03866174
- Testing
- Psilocybin, Niacin, Set and Setting (SaS) Protocol
- Where
- 11 sites in United States
- Volunteers
- 347 people
- Sponsor
- Usona Institute
Amphetamine-Related Disorders
Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder
This is a proof-of-concept randomized clinical trial of psilocybin-enhanced psychotherapy versus treatment-as-usual among individuals being treated for methamphetamine use disorder.
- Trial name
- NCT04982796
- Testing
- Psilocybin, Treatment-as-usual
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Portland VA Research Foundation, Inc
Treatment-Resistant Major Depressive Disorder
Understanding Music and Mindfulness Preferences in Psilocybin-Assisted Psychotherapy
The goal of this pilot clinical trial is to learn whether it is feasible to individually tailor psilocybin-assisted psychotherapy (PAP) for people with treatment-resistant depression (TRD) based on their personal preferences.
- Trial name
- PPP (NCT07373535)
- Testing
- Psilocybin 25mg, Music-centered psilocybin-assisted therapy, Mindfulness-centered psilocybin-assisted therapy
- Where
- 2 sites in Canada
- Volunteers
- 16 people
- Sponsor
- Kyle Greenway
MDD
Cancer Related Major Depression Treated With a Single Dose of Psilocybin
The goal of this randomized placebo controlled trial is to compare the antidepressant effect of a single oral dose of psilocybin 25 mg compared to 1 mg in 100 patients with cancer related major depressive disorder.
- Trial name
- CAPSI (NCT06319378)
- Testing
- psilocybin 25 mg sod, psilocybin 1 mg sod
- Where
- 4 sites in Sweden
- Volunteers
- 100 people
- Sponsor
- Section for Affective Disorders; Northern Stockholm Psychiatry